- Home
- TOPS vs TOVX Comparison
TOPS vs TOVX Comparison
Compare TOPS & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TOPS | TOVX |
|---|---|---|
| Founded | 2000 | 2001 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 14.7M |
| IPO Year | 2004 | 2012 |
Fundamental Metrics
Financial Performance| Metric | TOPS | TOVX |
|---|---|---|
| Price | $0.89 | $0.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 494.4K | ★ 11.8M |
| Earning Date | 04-01-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.85 | $0.16 |
| 52 Week High | $7.40 | $0.86 |
Technical Indicators
Market Signals| Indicator | TOPS | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 32.56 | 40.67 |
| Support Level | $0.85 | $0.18 |
| Resistance Level | $1.30 | $0.28 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 13.37 | 11.51 |
Price Performance
Historical ComparisonAbout TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.